COVID-19 UpdatesFree Study: Hydroxychloroquine doesn’t improve survival in hospitalized COVID-19 patients, but tocilizumab does May 29, 2020Vol.46 No.22
COVID-19 UpdatesFree Genentech begins phase III trial of tocilizumab + remdesivir in hospitalized patients with severe COVID-19 pneumonia May 29, 2020Vol.46 No.22
COVID-19 UpdatesFree UMich develops app that calculates risk of delaying cancer care during COVID-19 May 29, 2020Vol.46 No.22
COVID-19 UpdatesFree ACS CAN survey: cancer patients increasingly face COVID-19 health impact May 29, 2020Vol.46 No.22
Conversation with The Cancer LetterCOVID-19 & CancerFree John Cleveland: How Moffitt will heal from conflict of interest trauma—and from COVID-19 May 29, 2020Vol.46 No.22By Matthew Bin Han Ong
COVID-19 & CancerFree Radiation oncology appointments plummeted in the COVID-19 pandemic—but seem to be rising again May 29, 2020Vol.46 No.22By Alexandria Carolan
COVID-19 & CancerFreeGuest Editorial CCC19 data point to extensive use of hydroxychloroquine, azithromycin, or both, by patients with cancer and COVID-19 May 29, 2020Vol.46 No.22By Otis W. Brawley
Conversation with The Cancer LetterCOVID-19 & CancerFree Ramon Parsons: How Mount Sinai did good science amid the COVID-19 deluge May 29, 2020Vol.46 No.22By Paul Goldberg
Drugs & TargetsFree Opdivo + Yervoy combination receives FDA approval for first-line mNSCLC (PD-L1 tumor expression ≥1%) May 22, 2020Vol.46 No.21
Drugs & TargetsFree Pomalidomide receives accelerated approval to for Kaposi sarcoma May 22, 2020Vol.46 No.21
